Cowen Questions Sales Growth Of Biogen Idec's MS Drug Tecfidera Seeking Alpha AVONEX® (interferon beta-1a), TYSABRI® (natalizumab) and RITUXAN® (rituximab) are Biogen's other primary drugs in the MS indication. These three brought in the vast majority of the company's $1.4 B in quarterly revenues ($736 million, $275 million and ... |
